YUNG Therapist Sidekick | $825,000 | (Oct 4, 2024)
Rezilient Health | $10,000,000 | (Oct 4, 2024)
kapa.ai | $3,200,000 | (Oct 4, 2024)
Vicebio
United Kingdom
- Londres, Angleterre, Royaume-Uni
- 24/09/2024
- Series B
- $100,000,000
Vicebio uses the molecular clamp technology to develop innovative vaccines against life-threatening respiratory viruses. The Molecular Clamp technology provide unique stabilisation of viral envelop glycoproteins making possible highly effective, ready-to-use, and multivalent single shot respiratory virus vaccines.
- Industry Biotechnology Research
- Website https://vicebio.com/
- LinkedIn https://www.linkedin.com/company/vicebio/
Related People
Emmanuel HanonFounder
Belgium -
Brussels Metropolitan Area
Research & Development leader, C-level Executive, with more than 20 years experience at GSK, last 7 years running the global vaccines RD for GSK. Led the discovery and development of five major Vaccines : Quadrivalent Influenza (Fluarix and Flulaval Quadrivalent), Shingles (Shingrix), Malaria (Mosquirix), RSV older adult, and MenABCWY 5-in-1 Vaccines.
Broad functional leadership experience includes R&D, medical, clinical, regulatory, technical CMC, manufacturing and quality operations. Expert in Immunology, Microbiology, and Vaccinology
Enara Bio | $32,500,000 | (Oct 4, 2024)
Paren | $3,000,000 | (Oct 4, 2024)
Avarra | $8,000,000 | (Oct 4, 2024)
Sober Sidekick by Empathy Health Tech | $2,800,000 | (Oct 4, 2024)
3Laws | $4,100,000 | (Oct 4, 2024)
Reducto | $8,400,000 | (Oct 4, 2024)
Integrated Biosciences, Inc. | $17,000,000 | (Oct 4, 2024)
Mstack Chemicals | $40,000,000 | (Oct 4, 2024)
FLORA (Flora Fertility) | $1,500,000 | (Oct 4, 2024)
AMAKA Studio | $2,000,000 | (Oct 4, 2024)